Buoyed by encouraging data for its lead drug for autosomal dominant polycystic kidney disease, Regulus Therapeutics has moved swiftly to file a financing that will give it
Dutch biotech InteRNA Technologies has raised €18.5 million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumo
UK researchers say they have developed an algorithm that is more accurate than current tools at predicting an individual’s risk of developing cardiovascular disease in the
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.